1. Pfizer's stock is rated 'Buy' with a projected 45% upside due to strong EPS growth and cost reduction initiatives; 2. Q4 FY2024 results showed significant earnings beats, with non-COVID sales up 12% YoY and adjusted EPS beating consensus by 37%; 3. Pfizer's robust R&D pipeline is expected to drive future growth and offset patent expirations.